The Science Journal of the American Association for Respiratory Care

2008 OPEN FORUM Abstracts


Mary J. Johnson1, Ann M. Johnson9, Mark W. Wignes3, Deborah L. Brown6, Lindsey R. Armstrong2, Elsa Z. Brown5, Brigitte M. Chorey11, Arcenio Galindo1, Guy A. Gallaugher12, Debra M. Mcdowell8, Vickie S. McNair4, Terri E. Nelson10, Jason A. Steiger7

Background: Mayo Clinic is comprised of more than 20 inpatient and outpatient facilities of varying sizes located in several states in three different regions of the country. As part of the Supply Chain Management process, the respiratory departments from the various sites were selected as the first product review team (PRT) to develop a formulary of products and were given the task of standardizing respiratory supplies in the following categories: disposable manual resuscitators, ventilator disposables, noninvasive disposables, tracheostomy tubes, nebulizers, spacers/holding chambers, peak flow meters, open and closed suction, and routine respiratory disposables. It was also the responsibility of this initial PRT, to develop a viable process for objectively deciding what products would be chosen. Participants on the team included representatives from Respiratory, Supply Chain Management, and VHA. Team members identified additional stakeholders for each product category and requested input where applicable.

The team worked several months to develop a structured process to identify products to be listed and to determine which should be included on the formulary. A mixture of web meetings, conference calls, and an intensive two day face-to-face meeting was conducted.

Financial details were available for review but were not the sole basis for the team's product recommendations. For each product category, non-financial selection questions were developed that addressed breadth of the product line including vendor cross references, product quality including clinical criteria, and vendor capabilities/services available.

Each vendor was invited to present their products using a strict set of guidelines. Using the specific product criteria, the team evaluated the products and made recommendations for items to be included in the formulary. Regardless of size or location, each facility's response was given the same weight.

Recommendations for all product categories have been made to the Mayo Clinic Commodity Committee (MCCC). Following final MCCC approval (expected May 2008) each facility will be responsible to convert to formulary products. Requests to use products not listed on the formulary will require supporting clinical evidence.

Overall, the product standardization is expected to improve patient care by decreasing both practice and product variability within the Mayo enterprise and to provide financial gains through reductions in supply chain costs.